News

Under the terms of the deal, which is anticipated to close by the end of the first quarter of this year, Lilly will pay $46.50 a share for

Suliqua is authorized for use in combination with metformin to improve glycemic control when this has not been provided by metformin alone or metformin combined with another oral

The deal, which gives Biogen a license to Forward Pharma’s intellectual property, could help the US company extend the life of Tecfidera. Under several circumstances outlined in the deal, Biogen will

Niraparib is being made available for eligible women in the U.S. with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to

The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial is investigating SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients

The trial’s original objective was the effect on progression-free survival (PFS) but the company has now added overall survival (OS), both for the combination and durvalumab monotherapy. The

The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005. The complaint was filed in the United States District Court

The Company has also entered into a grant-funded collaboration with Solentim, the developer of the Cell Metric and dedicated instrumentation for cell line development, to establish automated approaches for

Sulfatinib is an oral, novel angio-immunokinase inhibitor that selectively targets vascular endothelial growth factor receptor (“VEGFR”), fibroblast growth factor receptor (“FGFR”) and colony-stimulating factor-1 receptor (“CSF-1R”), three key